Vital Bio

Vital Bio

Desktop automated point-of-care blood testing

Overview

Vital Bio develops the VitalOne, a desktop automated platform for point-of-care lab testing. It brings lab-grade tests to primary care clinics, pharmacies, and in-home care, using a small blood sample to perform 50+ tests. The device runs hematology, clinical chemistry, and immunoassays in parallel and delivers results in about 20 minutes, with less than 30 seconds of hands-on time. It uses microfluidics, robotics, computer vision, and biochemistry to automate testing, and offers a patient app for result tracking. Compared to competitors, it combines multiple test types in one compact device, covers roughly 95% of routine lab orders, and enables clinicians to test, diagnose, and treat in a single visit. Vital Bio aims to disrupt diagnostics by making testing more accessible and reducing delays in patient care, targeting faster, on-site decision making in clinics, pharmacies, and home care settings.

About Vital Bio

Simplify's Rating
Why Vital Bio is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Robotics & Automation

AI & Machine Learning

Healthcare

Company Size

201-500

Company Stage

Early VC

Total Funding

$48M

Headquarters

Mississauga, Canada

Founded

2018

Get referred to Vital Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VitalBio's June 2026 website update shows active product refinement and menu expansion.
  • Multi-city pilot plans across U.S. and Europe indicate customer validation momentum in 2026.
  • Board additions and prior Labcorp backing strengthen go-to-market and regulatory navigation.

What critics are saying

  • VitalBio still lacks public clinical validation; 2026 website only states development claims.
  • Series C chatter on April 7, 2026 signals capital dependence before commercialization.
  • Theranos-shaped skepticism kills adoption if VitalOne misses accuracy, reimbursement, or workflow integration.

What makes Vital Bio unique

  • VitalOne uses 600 microliters and 20-minute lab-grade testing in clinics.
  • VitalBio's 2026 site update claims room-temperature consumables and under-30-second hands-on time.
  • Douglas Bryant joined VitalBio's board, signaling diagnostics execution credibility from QuidelOrtho.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$48M

Above

Industry Average

Funded Over

1 Rounds

Early VC funding comparison data is currently unavailable. We're working to provide this information soon!
Early VC Funding Comparison
Coming Soon

Benefits

Competitive compensation and benefits package

Professional Development Budget

Conference Attendance Budget

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-2%
Longevity.Technology
Jul 27th, 2023
Vital Biosciences raises $48m for revolutionary blood diagnostic tech

Backers include Sam Altman and Marc Benioff as company seeks to create accessible diagnostics and expedite clinical interventions.

BetaKit
Jul 26th, 2023
Vital Biosciences reveals blood-testing solution

After the bloody mess at Theranos, Vital is among the new wave of startups developing accessible diagnostics.

Bloomberg
Jul 24th, 2023
Sam Altman, Valley VCs Bet $48 Million on Blood-Testing Startup

Years after Theranos, Vital Biosciences wants to prove Silicon Valley really can disrupt blood testing.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Vital Bio right now.

Find jobs on Simplify and start your career today

We update Vital Bio's jobs every few hours, so check again soon! Browse all jobs →